American technology firm Medidata, a subsidiary of Dassault Systèmes, has launched an advanced, intuitive platform called myMedidata for patients.

The myMedidata platform will enable flexible clinical trials participation for new vaccines.

It is designed to support research studies and speed up scientific understanding of the virus. Its first release includes a research-based Covid-19 symptom tracker.

The technology firm noted that the app will provide sponsors the ability to collect symptoms directly from research participants who may otherwise not be able to continue with traditional site visits.

This app also allows researchers to enrol huge registries of individuals to monitor their health status with respect to coronavirus.

Medidata co-founder and co-CEO Glen de Vries said: “It is critical for the life sciences industry to understand the effects of SARS-CoV-2 on patients, and to find ways to forge ahead with research across all therapeutic areas, from Covid-19 to cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The early launch of myMedidata allows sponsors to gather patient-reported Covid-19 symptoms in ongoing and new research programmes.”

The intuitive platform provides a comprehensive, integrated tool set for all aspects of patient-centric research.

The tool set includes eConsent, an electronic patient consent system for clinical trial participation, an electronic clinical outcomes assessment (eCOA), and an electronic patient-reported outcomes (ePRO).

Also included are wearable sensors that collect data from biosensors and wearable technology, as well as virtual trials.

With the help of myMedidata platform, patients will be able to view their own clinical data, both current and historical. It also helps increase their engagement with the study team.

The platform was built using insights generated by Medidata’s ‘Patient Centricity by Design’ framework.

Medidata mHealth senior vice-president Anthony Costello said: “Therapeutics and vaccines cannot be tested without the most critical components in clinical research, the patients, and their ability to participate.

“Making research more patient-centric and giving patients the ability to virtually access and actively engage in their own health care needs to be the new normal.”

In February, Medidata and Project ALS entered a research partnership in order to develop new therapeutic strategies for the treatment of Amyotrophic lateral sclerosis (ALS).